Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease
- 1 July 2000
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 86 (1) , 107-110
- https://doi.org/10.1016/s0002-9149(00)00840-7
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 monthsJournal of the American College of Cardiology, 1999
- A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve RegurgitationNew England Journal of Medicine, 1998
- The Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetite-Suppressant DrugsNew England Journal of Medicine, 1998
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Quantitation of aortic regurgitation by Doppler echocardiography: A practical approachAmerican Heart Journal, 1995
- Quantitative assessment of mitral regurgitation by doppler color flow imaging: Angiographic and hemodynamic correlationsJournal of the American College of Cardiology, 1989
- Evaluation of aortic insufficiency by Doppler color flow mappingJournal of the American College of Cardiology, 1987
- Continuous wave doppler determination of right ventricular pressure: A simultaneous Doppler-catheterization study in 127 patientsJournal of the American College of Cardiology, 1985
- Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave doppler ultrasoundJournal of the American College of Cardiology, 1985
- Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.Circulation, 1984